neurosurgical focus
tients with intramedullary lesions who underwent surgical treatment, a strategy of maximal removal was pursued. Of these 397 patients, the clinical findings in our cohort of 22 patients will be reviewed.
methods
This study is a retrospective analysis of data from 22 patients who were surgically treated for ISCM. Hospital data collected over a period of 22 years (1992-2014) , both at the time of treatment and at follow-up where available, were used. Six patients were treated before 2005, and 16 between 2006 and 2014, 15 of them within the last 4 years of the range, indicating a trend of higher incidence. The mean age of the patients was 55 years. No pediatric patients were included. Imaging was based on MRI in T1-and T2-weighted images with and without gadolinium in sagittal, axial, and coronal slices. Histological examinations were performed in-house with standard histopathological and immunohistological staining. Data obtained from the hospital archives included demographics, histopathological diagnoses of primary cancer, site of primary cancer, clinical symptoms leading to the diagnosis of ISCM, time since the primary cancer was diagnosed, pre-and postoperative neurological deficit using the simplified McCormick Scale functional classification, 41 location of the spinal metastasis, approximate radiological size of the metastasis, methods used during surgery, extent of resection, further treatments postoperatively, and ambulatory status at last follow-up. The extent of resection was based on the judgment of the surgeon and the postoperative MRI.
The McCormick Scale (simplified) is a functional classification of intramedullary spinal cord tumors with the appropriate validation. This was used to evaluate the clinical condition of the patients pre-and postoperatively, as well as in the follow-up (Table 1) . 41 Data are shown as the mean. Descriptive statistics were used to characterize the study population. The Student t-test was used to compare means of metric variables.
results demographic data
Since 1986, 397 intramedullary lesions have been treated in our institution, but metastases have been part of the spectrum only since 1992. Since then, 22 cases have been treated, with the frequency markedly increasing during the last 4 years of this analysis.
Thirteen male patients and 9 female patients were treated (Tables 2 and 3 ). The mean age among all patients was 55 years (range 21-86 years). On average, the male population was younger than the female population (p = 0.48). The mean age of men was 52 years (range 21-86 years). The mean age of women was 58 years (range 33-79 years). Metastases in the cervical and thoracic spine were identified in 77% of patients (n = 17), whereas metastases in the thoracolumbar region (i.e., conus medullaris) could be identified only in 23% of patients (n = 5). The timespan from primary cancer diagnosis to the development of symptomatic spinal metastases ranged from 0 to 285 months, with a mean interval of 38 months. In women, the period of time from primary cancer diagnosis to spinal metastasis was an average of 55.8 months. The corresponding period of time in men was remarkably shorter, with an average of 25.5 months (p = 0.35).
In 17 cases, the primary cancer was known or could be identified after obtaining the histopathology of the spinal metastasis. Lung cancer was the most frequent primary malignant disease (5 cases), followed by brain and breast cancers (3 cases each). Malignant melanoma was found twice. Bladder, prostate, ovarian, and kidney cancers, each represented by 1 case, were rare events. The brain metastases originated from 1 each anaplastic astrocytoma, ependymoma, and medulloblastoma.
In 8 patients, spinal metastases were the first clinical manifestation of malignant disease, thus representing a cancer of unknown primary (CUP) syndrome. In 5 of these patients, there was still no finding of a primary malignant tumor in subsequent staging. In 1 patient, the origin of the primary tumor was still unknown 12 months after treatment of ISCM. Another patient, in whom a renal carcinoma was the most probable origin of malignancy, died 4 months after spinal surgery without confirmation of the primary tumor source. Eleven patients (50%) had additional metastases at the time of presentation, 9 of them (41%) with tumors that had metastasized into the brain, 4 into the bone and liver, and 2 into the lung and lymph nodes. One patient had a skin metastasis (melanoma).
Fifty-nine percent of patients (n = 13) showed only mild clinical symptoms on the day of admission and were still able to walk autonomously (McCormick Scale Grade I or II). Eighteen percent of patients (n = 4) were severely disabled, with McCormick Scale Grade IV. Dysesthesia was the most common clinical symptom, with 77% of the study population reporting it before the time of surgery. The second-most common clinical symptom was paresis (68% of patients). Only 5 patients (23%) showed urinary and/or anal disorders.
Findings on mri
In each case, the radiological finding was obtained by an MRI with and without gadolinium enhancement. T1 and T2 imaging sequences were obtained. The typical enhancement was an intramedullary nodulus, which could be seen in all but 1 case ( Figs. 1 and 2 ). In this 1 case, which proved to be a metastasis of an anaplastic astrocytoma WHO Grade III, there was no enhancement in the gadolinium-enhanced T1 sequence, but the tumor could be clearly seen in the T2 FLAIR sequence (Fig. 3) . * Intravenous corticosteroids refer to intravenous administration of methylprednisolone (dependent on the patient's weight) over a period of 24 hours; Sono means ultrasound was additionally used during surgery to evaluate extent of resection (before myelotomy, ultrasound is used routinely).
The assumable volume of the tumor, where length (l), width (w), and depth (d) could be obtained, was calculated using the equation for ellipsoid volumes: vs = v = 4/3 p * l * w * d. Fifteen tumors could be calculated with a mean volume of 2980 ml, ranging from 513 to 8360 ml. In the remaining 7 patients, only 2 values could be established due to lack of original MRI data. Therefore, a volume could not be calculated. However, volume did not correlate with length of survival, neurological symptoms, extent of resection, or origin of the tumor.
therapy
All 22 patients underwent microsurgical treatment, with 1 biopsy and 21 resections. In 7 patients (32%), a total resection was obtained. In 12 patients (55%), the final degree of resection could be described as subtotal (small layers on the border zone to the healthy spinal cord were left intentionally due to electrophysiological changes), and in 2 patients the tumor was only partly removed. In 77% of patients, a hemi-laminectomy or an osteoplastic laminotomy with reconstruction of the posterior spinal column was conducted to reach the intradural pathology. In the remaining 5 patients, a corpectomy (n = 1) or laminectomy (n = 4) was performed. Only in 2 patients (9%) was > 2 levels of lamina opening necessary to obtain the whole dimension of the tumor. After opening the dura, the spinal cord was approached through the sulcus medianus posterior, proving to be the approach with the lowest chance of neurological side effects.
Ultrasound was used in all cases to identify the dimension of the tumor prior to resection, especially in cases where the tumor did not reach the dorsal surface and therefore could not be identified visually through the mi- croscope. Besides ultrasound, further methods used during surgery included the application of intravenous corticosteroids, CO 2 laser, Cavitron ultrasonic surgical aspirator (CUSA), and intraoperative monitoring (IOM). Continuous intra-and postoperative administration of weightdependent intravenous corticosteroids over 24 hours was conducted in all cases, with the aim to diminish swelling of the spinal cord. The CO 2 laser (Surgilase 25) was used 10 times (in 45% of patients). In 6 patients, ultrasound was additionally used during the tumor preparation to identify the borders to the healthy tissue. IOM was applied in 82% of patients. In 3 patients (14%), a CUSA was used.
Postoperatively, 6 patients underwent radiation of the resected area with up to 30 Gy, 7 had systemic chemotherapy, and 4 had a combination of these 2 treatments. In 2 cases, no further therapy was applied. In 1 case, a patient with a CUP did not want any further therapy, and the patient was discharged with no neurological symptoms. The source of the metastasis was still unknown 12 months after surgery, and the patient still did not show any neurological deficit.
Due to a general deterioration in 2 patients during the weeks after surgery, no further therapy was conducted in these cases. One patient with a kidney carcinoma treated with postsurgery radiation relapsed after 11 months at the same site and underwent a second surgery due to clinical worsening. A patient with a malignant melanoma showed a meningeal carcinomatous spreading in the follow-up MRI after 22 months and received a ventriculoperitoneal shunt 2 months later. Only 1 patient had a postoperative complication (a dural leakage), which had to be revised surgically.
One to 2 days after surgery, 11 of 19 patients (58%) showed no neurological difference, with 4 patients (21%) improving and 4 patients (21%) worsening. Immediately after surgery, 11 patients (58%) had either more or less trouble walking, compared with 7 patients (37%) before surgery. Although the clinical outcome immediately after surgery showed a decrease in "walking safely" as determined by the mean McCormick Scale grade, there was no change in the Student's t-test (p = 1.0).
For 5 patients who were treated before the year 1999, valid follow-up information could not be obtained. The last follow-up time for the patients still alive (n = 17) was a mean of 6.24 months (range 2-22 months) from the time of surgery. Death was confirmed in 11 patients, with a mean survival time of 11.6 months after surgery; the shortest survival time was 2 months and the longest was 30 months (data not shown in Table 3 ).
The clinical status represented by the McCormick Scale grade in the 17 patients for whom follow-up data were available showed a mean of 2.12, where 6 patients had almost no clinical disability (McCormick Scale Grade I) and 2 patients were severely disabled (McCormick Scale Grade IV). Compared with the clinical status 1-2 days after surgery, there was an improvement in the McCormick Scale grade at the last follow-up from 2.47 to 2.12 (p = 0.009). Likewise, an improvement was detected when comparing the preoperative status (2.45) with the last follow-up status (2.12; p = 0.029).
discussion
The occurrence of ISCM during the course of a malignant disease is still very rare. 8, 22, 23, 45, 48, 51 Nevertheless, with improved survival due to more effective treatments for many cancers, the incidence of ISCM will increase. This is already reflected by a continuous growth in the number of cases published in recent years (Fig. 4) . Our findings support this trend, with almost 60% of all ISCM treated in the last 3 years out of a period of 22 years. There are a rising number of reports on the medical treatment of ISCM. However, generally applicable therapy algorithms are only just emerging. One explanation might be the considerable inconsistencies of published data in terms of localization, treatment option, and outcome of cancer patients with ISCM.
Comparing our series with other published reports, we find comparable data in terms of mean age at ISCM presentation (55 years) and delay of diagnosis. 8, 22, 51 Interesting within this context is the fact that the delay in diagnosis of spinal pathologies shows a similar difference between men and women in spinal dural arteriovenous malformations, indicating that the often insidious onset of symptoms is frequently misinterpreted in women.
With respect to distribution between men and women, as well as localization of ISCM in the spinal cord, there is no clear picture emerging. In our series, 41% of ISCM were found in the cervical region, followed by the thoracic spine (36%). Only 23% were located in the conus medullaris, which is in line with the findings of Kalayci et al. 8 who describe the most common site of ISCM as in the conus medullaris (11/19; 58%). Our experience, with lung cancer being the primary tumor (n = 5, 23%), followed by breast cancer (n = 3, 14%), is shared with other publications. 4, 8, 18, 22, 26, 32, 34, 37, 39, 40, 43, 49 The findings of systemic spreading are also similar to other published data. Only 1 patient showed > 1 ISCM at the time of surgery. Nine patients (41%) had no other metastatic manifestations, leaving more than 50% with systemic migration, of which almost 80% proved to have brain metastases. 5, 8, 22, 30 The metastatic spread of a malignant disease into the CNS, and especially into the spinal cord, is associated with a very poor prognosis, limiting the time of survival. 4, 5, 8, 26, 37, 51 Within our cohort, only 3 patients (14%) had concom- itant brain metastasis. One proved to be a metastasis of an unknown medulloblastoma in the cerebellum. Only very few cases of this entity are published. 19, 27 The second proved to be a metastasis originating from an ependymoma WHO Grade III, diagnosed in the brain 41 months prior to the spinal occurrence. Unfortunately, as these cases were treated in 1992 and 1999, respectively, the patients were lost to follow-up. The third brain metastasis originated from an anaplastic astrocytoma WHO Grade III, which was diagnosed 54 months earlier. ISCM was located in the cervical spine, and after biopsy in 2014, the patient was treated with radiation. The patient's neurological functions declined after biopsy (raising the McCormick Scale grade from II to III) and did not improve over time. However, the patient was still alive 6 months after surgery, with stable neurological impairment.
In 2 patients (9%), a malignant melanoma proved to be the primary tumor, the percentage being similar to other published reports. 17, 33, 51 The remaining histologies-small cell renal, bladder, prostate, and ovarian carcinomaswere represented by 1 case each. A review of the literature shows that these obviously rare types of ISCM are usually represented only by case reports. 1, 2, 7, 9, 13, 14, 16, 21, 28, 35, 36 Interestingly, we encountered 5 cases (23%) of ISCM as the primary finding of a malignant disease, which is very consistent with the findings of Kalayci et al. 22 but stands in contrast to those of Dam-Hieu et al. 8 In the latter series, every patient except for 1 had a previously diagnosed tumor. 8, 22 In the case of 1 patient in our cohort, the origin of the primary tumor was still unknown 12 months after initial diagnosis. No second treatment after surgery has been conducted due to the decision of the patient and the absence of clinical impairment. This suggests that although ISCM are known to be a sign for poor prognosis, they still do not predict a fast lethal outcome in every case. Furthermore, length of survival apparently does not depend on the existence or absence of other metastatic manifestations. One patient in our series presented with a neuroendocrine cancer without further systemic spreading but died 3 months after surgical intervention. Another patient, diagnosed with the same primary tumor and who also showed brain metastases at the time of surgery, died 30 months later. ISCM due to malignant melanoma as a primary cancer seems to be associated with a longer length of survival. 33 One patient developed a systemic meningeal carcinomatous after 22 months and received a ventriculoperitoneal shunt 2 months later. The last follow-up was after 25 months. The second patient with ISCM of malignant melanoma was treated in 2014 and is still alive. This finding is in line with the results of Wilson et al. 51 as well as Conill et al. 4 Using an ellipsoid volume assumption, taking into account peak open volume in width, length, and depth presented on the gadolinium-enhanced MRI before surgery, we could not find any correlation relating to length of survival, the McCormick Scale grade before and after surgery, tumor origin, or degree of resection. As there is no mention of any connection between size and any parameter in the literature, we cannot compare these findings with other authors' experiences.
Of the 18 patients (we were able to obtain up-to-date information from their family doctor), 11 died. In this group, the mean length of survival after spine surgery was 11.6 months. This is distinctly longer compared with reported survival times for many other series and meta-analyses. 8, 22, 51 Comparing conservatively treated patients with surgically treated ISCM, Kalayci et al. demonstrated a surgical benefit in terms of increasing the length of survival from 5 months to 9.4 months, suggesting that surgical removal of the tumor without much delay has a positive effect on the further development of the disease. 22 However, Wilson et al., 51 as well as Watanabe et al., 48 could not find a benefit from surgery concerning the length of survival in their respective series. Nevertheless, their patients had preoperative urinary retention, which is accompanied by a progressive neurological deficit and poor prognosis (in our series, only 5 cases).
Surgical resection of an ISCM should, if chosen as the primary therapy, aim for a total resection. Considering the importance of total tumor resection in the case of cerebral metastases, one could postulate a similar importance when surgically removing ISCM. On the one hand, similar to intracranial metastases, ISCM are often well delineated, allowing for a dissection plane such that gross total resection can be achieved with minimal parenchymal injury. On the other hand, as there is more edema in the parenchymal tissue than in the well-differentiated intrinsic intramedullary tumors, there is an increased vulnerability. Perioperative neuroprotection with high-dose methylprednisolone is used on a regular basis in combination with an IOM as feedback for possible surgical stress, so that surgical steps can be adapted and postsurgical impairment minimized. 25, 50 Intraoperative ultrasound is also used regularly to confirm adequate extent of exposure before opening the dura and to assess extent of tumor resection.
12
A CO 2 laser is useful for minimizing mechanical stress during resection of an ISCM. It was applied in 10 cases in our series. Using all or a combination of these methods, it was possible to achieve at least a subtotal resection of the tumor in 85% of cases. Due to the heterogeneous origin of the primary histology, there is great variation in surface texture and infiltration at the tumor border. Therefore, in some cases, a small infiltrative tumorous layer was left deliberately. To enhance resection in these cases, a defocused, lowered-intensity CO 2 laser coagulation after resection of the main tumor mass was performed. In the postoperative MRI, no contrast-enhanced tumor could be seen. In 7 patients (32%), the surgeon described the anticipated total resection, which could be confirmed by postoperative MRI, showing no enhancement after gadolinium application. In 3 cases, only biopsy or partial removal was possible due to distinctive adhesions and worsening of intraoperative neuromonitoring.
Gasser et al. analyzed 146 spinal cord tumors, 13 of which were metastases, and postulated that radical resection depends on histology alone. Their data showed that sarcomas and poorly differentiated carcinomas could not be totally resected due to lack of a clear border between the tumor and the spinal cord. 15 In our data, there was no correlation between the extent of resection and the postoperative clinical outcome or length of survival, which was also described by Gasser et al.
15
When extrapolating treatment of CNS metastases to the spinal cord, radiation therapy and chemotherapy have to be evaluated as part of treatment options. Radiation is usually considered for patients without neurological symptoms and can be well tolerated if the correct indications are made. 8, 31, 38, 44, 47 On the other hand, Lee et al., 26 in a series of 11 patients undergoing radiotherapy and 1 patient without treatment, and Conill et al. 4 reporting on 6 cases treated with radiotherapy combined with steroids, showed that after a short period of clinical improvement, a rather fast decline occurred in neurological functions, sometimes within only a few days. Thus, one could assume that unless radiation leads to an expected rapid shrinking of the tumor, surgery should be considered even when patients are oligosymptomatic.
Surgery is usually offered to patients suffering from neurological impairment or in the case of an unknown primary where a tissue diagnosis is required. 30, 44, 47, 51 Kalayci et al., having analyzed 32 published cases where surgery on ISCM was performed, showed that no patients developed new postoperative neurological deficits and an overall clinical improvement was found, with the length of survival being nearly twice as long compared with patients treated conservatively. 22 Our study did not compare different modalities in the therapy of ISCM. Thus, we cannot answer the question of which therapy is better to use concerning postinterventional clinical decline or length of survival. It should be acknowledged that randomized trials to answer these clinical questions will probably never be performed due to recruitment barriers. But as can be seen throughout data published to date, each case must be considered individually to offer the best possible treatment. The different modalities involved-neurosurgery, radiotherapy, and oncology-must work closely together to achieve this. Surgery should be considered for the patient who shows fast neurological impairment, taking into consideration the primary disease (if known), the prognosis from the oncological point of view, and the decision of the patient. The preoperative neurological condition seems to be a reliable predictive factor for functional outcome after surgery and must therefore be taken into consideration when advising the patient. 8, 42, 51 In the future, with an expected higher incidence of ISCM, initial neurological symptoms should be taken seriously and proper diagnostic measures initiated accordingly. Increasing neurological impairment seems to lead to a poor neurological outcome after surgery; thus, time is essential, the goal being to provide as much good quality of life as possible.
In cases of primary brain tumors or brain metastases, maximizing cytoreduction is known to have a positive effect on length of survival. This may also be essential in the case of ISCM and therefore should be set as the main goal of surgical treatment. 24 Second, early decompression of the spinal cord may result in preserving or even improving neurological functions, as the growing understanding of spondylotic myelopathy has shown in the past. 11 Taking all of this into account, the timely surgical treatment of ISCM must be considered an option to protect the remaining functional intact spinal cord. Technology for traction-free dissection, IOM, corticosteroids, potentially fluorescence guidance, and good anatomical knowledge help to achieve positive results.
conclusions
The occurrence of ISCM in the course of malignant disease is usually predictive of shortened life expectancy and is often associated with severe and worsening neurological deficits. We showed in 22 patients that surgery on ISCM, conducted under certain preconditions, can extend length of survival. The knowledge of incidence of intramedullary metastasis and its course is still very heterogeneous.
It depends on the histology of the primary tumor, whether it has spread to other organs, operative and conservative treatment strategies, and the patient's overall condition. In the future, a sophisticated treatment algorithm will be of great importance, as the incidence of ISCM will probably increase further. Larger, prospective studies are needed.
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